What changed, and what it actually shows
Published human studies, new trials, status changes, regulatory announcements, corrections and safety findings. Every item gets the same treatment: what was found, and what it does not establish.
- PubMed-linked
- ClinicalTrials.gov data
- Limitations stated
Feed
Latest
- Regulatory
Compounding advisory discussion is not an approval — reading the July record
A committee discussing or nominating a substance tells you the substance is being examined. It does not tell you the substance works, is safe, or may be sold. We break the July record into our five standings: under consideration, recommended, listed, approved, not approved.
- Human studyPromising
Post-discontinuation weight regain after incretin therapy
Follow-up data continue to show substantial regain after stopping. The clinically useful question is shifting from how much weight comes off to what a durable maintenance plan looks like.
- SafetyEstablished
Mislabelled peptide products found in independent testing
Identity and purity failures continue to appear in consumer-directed peptide products. This is a supply-chain risk that exists independently of whether a molecule has any biological merit.
- Correction
Correction: BPC-157 regulatory note
Our earlier note could be read as implying that compounding-committee consideration indicated progress toward approval. It does not. The note has been rewritten and the change logged on the dossier.
Related:BPC-157 - New trial
New phase 3 registration in the triple-agonist class
Registration is a milestone in a development programme, not a result. We will report outcomes when they are published, not when they are announced by press release.
Related:Retatrutide - CommentaryPreliminary
Why lean-mass loss deserves more attention than it gets
Body-composition data from incretin trials is often reported as a footnote. For older adults it may be the most functionally important number in the study.
Get this as a weekly brief
The developments that matter, with evidence grades, sources and regulatory context — once a week, no protocols, no product pitches.